Genentech's atezolizumab has been granted a fast review in the US for some cases of advanced non-small cell lung cancer. The US Food and Drug Administration has granted a Priority Review for the ...

Atezolizumab is a monoclonal antibody that works to hinder interactions between programmed death ligand-1 (PD-L1) and programmed cell death-1 (PD-1) receptors, which are overexpressed in a variety ...

or Tecentriq (atezolizumab), are another option that may affect quality of life and survival times in specific cases. The five-year survival rate for someone with non-small cell lung cancer varies ...

Phase III IMvoke010 trial found that maintenance treatment with Tecentriq (atezolizumab) did not significantly improve ...

Lung cancer is the third leading cause of cancer ... Immunotherapy drugs used for extensive-stage SCLC include: Tecentriq (atezolizumab) Imfinzi (durvalumab) Imdelltra (tarlatamab) If cancer ...

The first patient with small cell lung cancer has been dosed in a trial of peluntamig ... to evaluate peluntamig in combination with the anti-PD-L1 therapy Tecentriq (atezolizumab). Dose-limiting ...

NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) for untreated advanced or recurrent non-small-cell lung cancer when platinum-doublet chemotherapy is ...

Thymic carcinoma, a rare cancer, is often associated with poor prognosis in advanced or recurrent stages. However, its rarity ...

Roche has suffered a setback with its much-anticipated pairing of anti-TIGIT antibody tiragolumab and PD-L1 inhibitor Tecentriq in small cell lung cancer (SCLC), in a blow to its ambitions in ...

Read more about A trial of MK-7684A and chemotherapy for small cell lung cancer (KeyVibe-008) A trial of lurbinectedin and atezolizumab to improve treatment for small cell lung cancer (IMforte) This ...